Abstract
The Wilms tumor 1 (WT1) gene encodes a transcription factor that was among the first tumor suppressor genes to be identified. Dependent on the splice variant, some WT1 isoforms can function as transcriptional regulators, whereas other WT1 proteins are presumably involved in RNA processing. The mechanisms by which WT1 regulates transcription and the identification of bona fide target genes have been difficult to study, which is partially due to the complex nature of the gene and its context specific functions. While the role of WT1 as a tumor suppressor in Wilms tumor is widely accepted, considerable evidence points to an oncogenic function in other tumors. Recent studies have provided new insights into the underlying mechanisms that lead to the development of Wilms tumor. In addition, a conditional Wt1 knockout mouse model and RNAi-mediated screening approaches have uncovered new functions for WT1 in development and tumorigenesis.
Keywords: Apoptosis, HTRA2, Igf2, oncogene, senescence, WT1, sumoylation, phosporylation, Tumorigenesis, epithelial-mesenchymal
Current Pediatric Reviews
Title: Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis
Volume: 7 Issue: 4
Author(s): Jorg Hartkamp
Affiliation:
Keywords: Apoptosis, HTRA2, Igf2, oncogene, senescence, WT1, sumoylation, phosporylation, Tumorigenesis, epithelial-mesenchymal
Abstract: The Wilms tumor 1 (WT1) gene encodes a transcription factor that was among the first tumor suppressor genes to be identified. Dependent on the splice variant, some WT1 isoforms can function as transcriptional regulators, whereas other WT1 proteins are presumably involved in RNA processing. The mechanisms by which WT1 regulates transcription and the identification of bona fide target genes have been difficult to study, which is partially due to the complex nature of the gene and its context specific functions. While the role of WT1 as a tumor suppressor in Wilms tumor is widely accepted, considerable evidence points to an oncogenic function in other tumors. Recent studies have provided new insights into the underlying mechanisms that lead to the development of Wilms tumor. In addition, a conditional Wt1 knockout mouse model and RNAi-mediated screening approaches have uncovered new functions for WT1 in development and tumorigenesis.
Export Options
About this article
Cite this article as:
Hartkamp Jorg, Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis, Current Pediatric Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339611796892373
DOI https://dx.doi.org/10.2174/157339611796892373 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Current Neuropharmacology CD133 Expressing Pericytes and Relationship to SDF-1 and CXCR4 in Spinal Cord Injury
Current Neurovascular Research Absorption, Pharmacokinetics and Disposition of Biodegradable Nanoscale Preparations
Current Drug Metabolism Kidney Diseases and Chemokines
Current Drug Targets Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Lipids as a Target for Drugs Modulating Multidrug Resistance of Cancer Cells
Current Drug Targets Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology Therapeutic Targets in Polycystic Liver Disease
Current Drug Targets Dose-Intensive Chemotherapy with Stem Cell Support as a Treatment Strategy for Bone and Soft-Tissue Sarcomas
Current Stem Cell Research & Therapy The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging Meridianins: Marine-Derived Potent Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors
Current Topics in Medicinal Chemistry From TGF-β to Cancer Therapy
Current Drug Targets Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry